findphrase.net
 

Phrases contain exact "meningococcal vaccine" from credible sources

EXACT :

Feb 11, 1998 · Context: Use of the quadrivalent meningococcal vaccine for control of outbreaks has increased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns in US civilian populations has not been assessed. Objectives: To evaluate the efficacy of the quadrivalent meningococcal vaccine against serogroup C meningococcal disease in a … <br><strong>Author:</strong> Nancy Rosenstein, Orin Levine, Jeffery P. Taylor, Deborah Evans, Brian D. Plikaytis, Jay D. Wenger, ... <br><strong>Publish Year:</strong> 1998
pubmed.ncbi.nlm.nih.gov


Sep 25, 2020 · This report compiles and summarizes all recommendations from CDC's Advisory Committee on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States. As a comprehensive summary and update of previously published recommendations, it replaces all previously published reports a …
pubmed.ncbi.nlm.nih.gov


Aug 02, 2021 · Background: Invasive meningococcal disease (IMD), caused by Neisseria meningitidis, leads to significant morbidity and mortality worldwide. This review aimed to establish the effectiveness of meningococcal vaccines at preventing IMD and N. …
pubmed.ncbi.nlm.nih.gov


Mar 27, 2017 · Background: Limited data are available describing the post-licensure safety of meningococcal vaccines, including Menveo®. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) to assess safety in all age groups.
pubmed.ncbi.nlm.nih.gov


There are 2 types of meningococcal vaccines available in the United States:<strong> Meningococcal conjugate or MenACWY vaccines (Menactra ® , Menveo ®, and MenQuadfi ®)</strong> …
www.cdc.gov


Feb 03, 2022 · Meningococcal vaccines<strong> protect against bacterial infections caused by Neisseria meningitidis.</strong> These bacteria are capable of causing meningococcal meningitis, a …
www.verywellhealth.com


Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They a… <br><strong>Routes of administration:</strong> … <br><strong>Trade names:</strong> Menactra, Menveo, Menomune, Others <br><strong>Vaccine type:</strong> Conjugate or polysaccharide
en.wikipedia.org


Aug 06, 2021 · <strong>Meningococcal</strong> ACWYvaccine can help protect against<strong> meningococcal</strong> disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can …
medlineplus.gov


Jul 04, 2022 · The meningococcal vaccine is an injection given to protect you from certain types of meningococcal disease. Meningococcal disease is an infection caused by meningococci …
www.drugs.com


A different meningococcal vaccine is available that can help protect against serogroup B. Meningococcal disease can cause meningitis (infection of the lining of the brain and spinal …
medlineplus.gov


What is meningococcal vaccine? Meningococcal vaccines are used to protect against meningococcal disease. Meningococcal disease is caused by a bacteria called Neisseria …
www.healthnavigator.org.nz


May 30, 2012 · The prevention of group B <strong>meningococcal</strong> disease has remained a challenge throughout this period. This review charts the history of the development of <strong>meningococcal vaccines</strong> and the importance of serological correlates of protection in their evaluation. <br><strong>Author:</strong> Caroline Vipond, Rory Care, Ian M. Feavers <br><strong>Publish Year:</strong> 2012
pubmed.ncbi.nlm.nih.gov


Mar 29, 2022 · There are currently three quadrivalent <strong>meningococcal vaccines</strong> (Serogroups A, C, W, Y) and two recombinant serogroup B <strong>vaccines</strong> available for use in the United States, and recommendations for <strong>vaccine</strong> use have changed rapidly in the past 10-15 years. This article summarizes updated ACIP recommendations for <strong>meningococcal vaccination</strong> for the ...
pubmed.ncbi.nlm.nih.gov


The risk of Henoch-Schönlein purpura (HSP) following <strong>vaccination</strong> with a group B <strong>meningococcal vaccine</strong> was assessed through active hospital safety monitoring. There was no increase in the relative incidence of HSP within 30 days after <strong>vaccination</strong> nor recurrence in HSP cases who received one or more f …
pubmed.ncbi.nlm.nih.gov


Conclusions: Although a <strong>meningococcal vaccine</strong> is available, meningococcus causes significant morbidity and mortality. Controversy exists over the <strong>meningococcal vaccine</strong> and its use. Students entering college who will be living in dormitories should be informed of the increased risk of <strong>meningococcal</strong> disease and be offered <strong>vaccination</strong>.
pubmed.ncbi.nlm.nih.gov


There are 2 types of meningococcal vaccines available in the United States:<strong> Meningococcal conjugate or MenACWY vaccines (Menactra ® , Menveo ®, and MenQuadfi ®)</strong> …
www.cdc.gov


Feb 03, 2022 · The side effects of meningococcal vaccines are similar to those normally seen with vaccines. They include<strong> redness at the injection site, soreness, muscle pain, headaches,</strong> …
www.verywellhealth.com


Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They a… <br><strong>Routes of administration:</strong> … <br><strong>Trade names:</strong> Menactra, Menveo, Menomune, Others <br><strong>Vaccine type:</strong> Conjugate or polysaccharide
en.wikipedia.org


The <strong>meningococcal vaccine</strong> protects you from four types of bacteria that cause <strong>meningococcal</strong> disease. This illness can cause meningitis , an infection of the lining around the brain or spinal …
www.webmd.com


Aug 06, 2021 · <strong>Meningococcal</strong> ACWYvaccine can help protect against<strong> meningococcal</strong> disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available that can …
medlineplus.gov


Aug 25, 2011 · According to the Provincial Meningococcal Vaccine Registry, a total of 1,428,463 individuals (aged 2 months to 20 years) received at least one dose of vaccine from November …
www.ncbi.nlm.nih.gov


Jan 01, 2004 · <strong>Meningococcal vaccines</strong>. <strong>Meningococcal</strong> meningitis and septicaemia are caused by various serogroups of Neisseria meningitidis. Endemic disease occurs worldwide …
www.who.int


Related keywords of "meningococcal vaccine" from credible sources

Phrases contain similar "meningococcal vaccine" from credible sources

SIMILAR :

By 1989, researchers in Havana had developed a Cuban meningococcal B and C vaccine, VA-MENGOC-BC, the world's first against serogroup B meningococcal disease. Its efficacy of 83% was demonstrated in a prospective, randomized, double-blind, placebo-controlled field study. Vaccine production used vesicle or proteoliposome technology for the first ... <br><strong>Author:</strong> V Gustavo Sierra-González <br><strong>Publish Year:</strong> 2019
pubmed.ncbi.nlm.nih.gov


Objective: This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate vaccine to prevent meningococcal disease from serogroups A, C, W, Y. Data sources: A literature review was conducted in PubMed, MEDLINE, and ClinicalTrials.gov from inception up to July 2021, using the search terms MenQuadfi, … <br><strong>Author:</strong> Jessica Huston, Kevin Galicia, Eric F Egelund <br><strong>Publish Year:</strong> 2021
pubmed.ncbi.nlm.nih.gov


Jul 01, 2021 · Background: From 2017, a statewide cluster randomized trial was conducted in South Australia to assess the impact of the meningococcal B vaccine 4CMenB on pharyngeal Neisseria meningitidis carriage in adolescents. Senior schools were randomized to receive the vaccine in 2017 (intervention) or 2018 (control). In this study we report the vaccine impact of … <br><strong>Author:</strong> Mark McMillan, Bing Wang, Ann P Koehler, Thomas R Sullivan, Helen S Marshall <br><strong>Publish Year:</strong> 2021
pubmed.ncbi.nlm.nih.gov


May 30, 2012 · For over a hundred years<strong> Neisseria meningitidis</strong> has been known to be one of the major causes of bacterial meningitis. However, effective vaccines were not developed until the latter part of the 20th century. The first of these were based on purified high molecular weight capsular polysaccharides and … <br><strong>Author:</strong> Caroline Vipond, Rory Care, Ian M. Feavers <br><strong>Publish Year:</strong> 2012
pubmed.ncbi.nlm.nih.gov


Dec 20, 2017 · Objectives: To summarize and critically evaluate the evidence on the impact and effectiveness of meningococcal vaccination programs around the world in order to inform decisionmaking in Latin America and the Caribbean. Methods: A review of the literature was conducted following several components of the Preferred Reporting Items for Systematic …
pubmed.ncbi.nlm.nih.gov


Apr 16, 2019 · Abstract. The discovery of<strong> vaccine antigens</strong> through whole genome sequencing (WGS) contrasts with the classical hypothesis-driven laboratory-based analysis of microbes to identify components to elicit protective immunity. This radical change in scientific direction and action in<strong> vaccine</strong> research is captured in the term reverse<strong> vaccinology.</strong>
pubmed.ncbi.nlm.nih.gov


Meningococcal disease is one of the most feared and serious infections in the young and its prevention by vaccination is an important goal. The high degree of antigenic variability of the organism makes the meningococcus a challenging target for vaccine prevention. Meningococcal polysaccharide vaccines against serogroup A and C are efficacious ...
pubmed.ncbi.nlm.nih.gov


Mar 29, 2022 · Neisseria meningitidis is an aerobic, gram-negative, diplococcus bacterium that is a leading cause of meningitis and sepsis in the United States. Particularly at-risk groups include those with complement deficiencies, people using complement inhibitors, individuals with anatomic or functional asplen …
pubmed.ncbi.nlm.nih.gov


Tetravalent serogroup A/C/W/Y conjugate vaccines are in late stage development. The use of serogroup B capsular polysaccharide as the basis for a vaccine for prevention of serogroup B meningococcal disease has proved problematic. The recent sequencing of the serogroup B genome led to the identification of additional, genome-derived, neisserial ...
pubmed.ncbi.nlm.nih.gov


Apr 27, 2002 · Neisseria meningitidis is a major cause of bacterial meningitis and sepsis. Polysaccharide-protein conjugate vaccines for prevention of group C disease have been licensed in Europe. Such vaccines for prevention of disease caused by groups A (which is associated with the greatest disease burden worldwide), Y, and W135 are being developed.
pubmed.ncbi.nlm.nih.gov


Apr 03, 2021 · Background: Although China's Expanded Program on Immunization (EPI) provides two doses of group A meningococcal polysaccharide vaccine (MPV-A) for children younger than 2 y, more self-paying group A and group C meningococcal polysaccharide conjugate vaccine (MCV-AC) has been used as an alternative to MPV-A, to prevent Neisseria meningitidis serogroup C …
pubmed.ncbi.nlm.nih.gov


Newly released meningococcal conjugate vaccines against N. meningitidis serogroup C have been highly efficacious in young children and adolescents, with minimal side effects. Conjugate vaccines targeting other important meningococcal serogroups (e.g., N. meningitidis serogroup A, responsible for the large pandemic outbreaks and the majority of ...
pubmed.ncbi.nlm.nih.gov


Elimination of meningococcal disease likely will require a novel approach to vaccine development, ideally incorporating a safe and effective antigen or antigens common to all meningoccocal serogroups. As a solely human pathogen, however, N. meningitidis has developed many tools with which to evade the human immune system, and likely will pose a ...
pubmed.ncbi.nlm.nih.gov


May 04, 2018 · Invasive meningococcal disease, although rare, can present as sudden, life-threatening disease with high risk of mortality or severe long-term sequelae. The main prevention strategy for invasive meningococcal disease in the United States is the routine vaccination of adolescents and other persons at …
pubmed.ncbi.nlm.nih.gov


Jul 03, 2021 · Meningococcal meningitis caused by Neisseria meningitidis is a reportable infectious disease in China, due to the high incidence of meningitis in the era before the availability of vaccines. The disease incidence was markedly reduced after meningococcal vaccination was introduced in the 1980s. Currently, there are polysaccharide, conjugate, and …
pubmed.ncbi.nlm.nih.gov


The<strong> meningococcal</strong> conjugate<strong> vaccine</strong> or<strong> MCV4</strong> was approved in 2005. It uses antigens taken from the polysaccharide capsule and then bound to a separate protein that targets the body's …
www.webmd.com


The meningococcal<strong> vaccine protects you from four types of bacteria that cause meningococcal disease.</strong> This illness can cause meningitis, an infection of the lining around …
www.webmd.com


The<strong> meningococcal</strong> conjugate<strong> vaccine (MenACWY) protects against four types of meningococcal bacteria (types A, C, W, and Y).</strong> It is recommended for all kids and teens …
kidshealth.org


Aug 25, 2011 · Although various <strong>vaccines</strong> against<strong> meningococcal</strong> disease have been available for more than 30 years, currently<strong> there is no vaccine to protect against all</strong> five<strong> of the</strong> …
www.ncbi.nlm.nih.gov


Meningococcal (muh-nin-jeh-KOK-el) disease used to cause thousands of serious infections every year. Thanks to vaccines, there are fewer cases of meningococcal disease in the United …
www.hhs.gov


Jan 04, 2022 · Meningococcal conjugate vaccine is used to prevent infection caused by serogroups A, C, W, and Y. This vaccine helps your body develop immunity to meningitis, but …
www.drugs.com


Aug 04, 2022 · Meningococcal conjugate vaccines were shown to achieve a seroresponse comparable to the MPSV4 and are able to elicit better immunologic memory [3]. Vaccine
www.vaccinesafety.edu


Jun 22, 2022 · June 22, 2022. An outbreak of <strong>meningococcal</strong> disease in Florida has caused at least 26 cases of the serious illness, an official from the Centers for Disease Control and Prevention said on ...
www.nytimes.com


Dec 01, 2012 · The <strong>meningococcal</strong> conjugate <strong>vaccines</strong> (MCV) are preferred for reasons of immunogenicity and persistence of immunity but are unavailable in India. Only the quadrivalent and bivalent <strong>meningococcal</strong> Ps <strong>vaccines</strong> (MPV) are available in India. The quadrivalent MPV is preferred for Haj pilgrims, international travelers and students in that it provides ...
pubmed.ncbi.nlm.nih.gov


Feb 11, 1998 · The <strong>meningococcal</strong> polysaccharide <strong>vaccine</strong> was effective against serogroup C <strong>meningococcal</strong> disease in this community outbreak. Although specific barriers to <strong>vaccination</strong> were not identified, older age was a risk factor for nonvaccination in the target population of 2- to 29-year-olds. In future outbrea … <br><strong>Author:</strong> Nancy Rosenstein, Orin Levine, Jeffery P. Taylor, Deborah Evans, Brian D. Plikaytis, Jay D. Wenger, ... <br><strong>Publish Year:</strong> 1998
pubmed.ncbi.nlm.nih.gov


Objective: This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate <strong>vaccine</strong> to prevent <strong>meningococcal</strong> disease from serogroups A, C, W, Y. Data sources: A literature review was conducted in PubMed, MEDLINE, and ClinicalTrials.gov from inception up to July 2021, using the search terms MenQuadfi, … <br><strong>Author:</strong> Jessica Huston, Kevin Galicia, Eric F Egelund <br><strong>Publish Year:</strong> 2021
pubmed.ncbi.nlm.nih.gov


Jul 01, 2021 · Background: From 2017, a statewide cluster randomized trial was conducted in South Australia to assess the impact of the <strong>meningococcal</strong> B <strong>vaccine</strong> 4CMenB on pharyngeal Neisseria meningitidis carriage in adolescents. Senior schools were randomized to receive the <strong>vaccine</strong> in 2017 (intervention) or 2018 (control). In this study we report the <strong>vaccine</strong> impact of …
pubmed.ncbi.nlm.nih.gov


Dec 20, 2017 · Results: In all, 32 studies were included, most of which evaluated the <strong>meningococcal</strong> C conjugate <strong>vaccine</strong>. Fourteen studies measured effectiveness and 30 measured impact. The effectiveness of polysaccharide <strong>vaccines</strong> was 65% - 83.7% (different age groups), while the effectiveness of the conjugate <strong>vaccines</strong> was 66% - 100%.
pubmed.ncbi.nlm.nih.gov


By 1989, researchers in Havana had developed a Cuban <strong>meningococcal</strong> B and C <strong>vaccine</strong>, VA-MENGOC-BC, the world's first against serogroup B <strong>meningococcal</strong> disease. Its efficacy of 83% was demonstrated in a prospective, randomized, double-blind, placebo-controlled field study. <strong>Vaccine</strong> production used vesicle or proteoliposome technology for the first ...
pubmed.ncbi.nlm.nih.gov


Apr 03, 2021 · Background: Although China's Expanded Program on Immunization (EPI) provides two doses of group A <strong>meningococcal</strong> polysaccharide <strong>vaccine</strong> (MPV-A) for children younger than 2 y, more self-paying group A and group C <strong>meningococcal</strong> polysaccharide conjugate <strong>vaccine</strong> (MCV-AC) has been used as an alternative to MPV-A, to prevent Neisseria meningitidis …
pubmed.ncbi.nlm.nih.gov


<p>While invasive <strong>meningococcal</strong> disease (IMD) is uncommon, it can result in serious sequelae and even death. In 2018 in the United States, the incidence of IMD per 100,000 people was 0.03 among adolescents 11-15 years of age, 0.10 among persons 16-23 years of age, and 0.83 among infants < 1 year of</p> …
pubmed.ncbi.nlm.nih.gov


Feb 25, 2018 · <strong>Meningococcal</strong> meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of <strong>vaccines</strong> (polysaccharide-based, glycoconjugate, protein-based and combined conjugate <strong>vaccines</strong>) that are approved to target five of the six disease-causing serogroups of the pathogen.
pubmed.ncbi.nlm.nih.gov


<strong>Meningococcal</strong> group C conjugate <strong>vaccines</strong> were first introduced to the UK in 1999. To date, the <strong>vaccines</strong> have been demonstrated to have an efficacy of approximately 90% and have since been adopted by other countries worldwide. The development of control tests used for lot release of <strong>meningococcal</strong> gro …
pubmed.ncbi.nlm.nih.gov


Purpose: Despite recommended routine <strong>vaccination</strong> with <strong>meningococcal</strong> conjugate <strong>vaccine</strong> (MenACWY) at ages 11-12 years with a booster at age 16 years, national estimates indicate MenACWY uptake is lower in older adolescents than younger adolescents. This study aimed to identify factors associated with MenACWY uptake among adolescents. ...
pubmed.ncbi.nlm.nih.gov


Tetravalent serogroup A/C/W/Y conjugate <strong>vaccines</strong> are in late stage development. The use of serogroup B capsular polysaccharide as the basis for a <strong>vaccine</strong> for prevention of serogroup B <strong>meningococcal</strong> disease has proved problematic. The recent sequencing of the serogroup B genome led to the identification of additional, genome-derived, neisserial ...
pubmed.ncbi.nlm.nih.gov


<strong>Meningococcal</strong> disease is one of the most feared and serious infections in the young and its prevention by <strong>vaccination</strong> is an important goal. The high degree of antigenic variability of the organism makes the meningococcus a challenging target for <strong>vaccine</strong> prevention. <strong>Meningococcal</strong> polysaccharide <strong>vaccines</strong> against serogroup A and C are efficacious ...
pubmed.ncbi.nlm.nih.gov


Conjugate <strong>vaccine</strong> technology has been very successfully used in childhood <strong>vaccines</strong> for the prevention of other bacterial meningitis pathogens, including <strong>vaccines</strong> against Haemophilus influenzae serotype b (Hib) and more recently, the seven- and nine-valent conjugate pneumococcal <strong>vaccines</strong>. Newly released <strong>meningococcal</strong> conjugate <strong>vaccines</strong> against N ...
pubmed.ncbi.nlm.nih.gov


New prevention approaches, such as <strong>vaccination</strong>, are needed. Outer membrane vesicle <strong>meningococcal</strong> serogroup B <strong>vaccines</strong> might be protective against gonorrhoea. We evaluated the effectiveness of a serogroup B <strong>meningococcal</strong> outer membrane vesicle <strong>vaccine</strong> (MenB-4C) against gonorrhoea in individuals aged 16-23 years in two US cities.
pubmed.ncbi.nlm.nih.gov


<strong>The meningococcal conjugate vaccine or MCV4 was</strong> approved in 2005. It uses antigens taken from the polysaccharide capsule and then bound to a separate protein that targets the body's …
www.webmd.com


The<strong> meningococcal conjugate vaccine (MenACWY) protects against four types of meningococcal bacteria (types A, C, W, and Y).</strong> It is recommended for all kids and teens …
kidshealth.org


<strong>Meningococcal (muh-nin-jeh-KOK-el) disease used to cause thousands of serious infections every year.</strong> Thanks to vaccines, there are fewer cases of meningococcal disease …
www.hhs.gov


Jan 04, 2022 · <strong>Meningococcal conjugate vaccine is used to prevent infection caused by serogroups A, C, W, and Y. This</strong> vaccine helps your body develop immunity to meningitis, …
www.drugs.com


Meningococcal vaccination for people in a special risk group Recommendations All infants, children and adults Any person from 6 weeks of age who wants to protect themselves against …
immunisationhandbook.health.gov.au


<strong>Meningococcal</strong> disease is one of the most feared and serious infections in the young and its prevention by <strong>vaccination</strong> is an important goal. The high degree of antigenic variability of the …
pubmed.ncbi.nlm.nih.gov


<strong>Meningococcal</strong> Meningitis. <strong>Meningococcal</strong> meningitis and septicaemia are caused by various serogroups of Neisseria meningitidis (meningococcus) which is an aerobic Gram-negative …
www.who.int



meningococcal vaccine

[meningococcal* ˌvækˈsin]